Is Xilio Therapeutics, Inc. (XLO) a Buy, Sell, or Hold?
NASDAQ : XLO
Xilio Therapeutics, Inc.
$8.87 USD
-$0.31 (-3.38%)
- Volume
- 7.12K
- Average Volume
- 43.68K
- Market Capitalization
- $58.32M
- P/E Ratio
- -5.95
- Dividend Yield
- 0.00%
- Price Target
- $98.00
- Year High
- $12.74
- Year Low
- $6.47
- Day High
- —
- Day Low
- —
- Payout Ratio
- $0.00
- Current Ratio
- $4.25
Company Overview
NASDAQ
Rene Russo
Biotechnology
Healthcare
XLO
76
US
USD
Liquidity Metrics
0.09
4.25
4.25
3.98
0.00
Sales & Valuation
$43.77M
0.91
23.82
-0.95
-0.32
Profitability
-$4.19
-$35.04M
-24.12%
-24.12%
-35.95%
-10.02%
P/E Metrics
-5.95
-0.03
-0.03
Analyst Price Target & Rating
$98.00
$98.00
$98.00
2/5
3 Analysts
-90.95%
Financial Health Scores
-2.76
2/9
$111.25M
$163.49M
$90.94M
-$31.3M
Key Metrics (TTM)
-$83.34M
-1.56
2.79
3.59
-117.24%
-34.65%
-2.09%
-95.04%
-25 days
Company Executives
| Name | Title |
|---|---|
| Uli Bialucha | Chief Scientific Officer |
| Ruth du Moulin | Senior Vice President of Medical Affairs |
| Katarina Luptakova | Chief Medical Officer |
| Christopher Frankenfield | Chief Financial Officer & Chief Operating Officer |
| Benjamin S. Harshbarger | Chief Legal Officer |
| Rene Russo BCPS | President, Chief Executive Officer & Director |
| Scott Coleman | Chief Development Officer |
| Caroline Hensley | Chief Legal Officer |
| Kevin Brennan | Senior Vice President of Finance & Accounting |
| Nathan McBride | Chief Information Officer |
Poll Results
No votes yet today — be the first to share your view!
About Xilio Therapeutics, Inc. (NASDAQ:XLO) Stock
Xilio Therapeutics, Inc. is a clinical-stage biotechnology firm dedicated to crafting immunotherapies aimed at strengthening the immune systems of cancer patients. A key part of their pipeline is XTX101, a tumor-selective anti-CTLA-4 monoclonal antibody that is currently undergoing Phase 1/2 clinical trials for various solid tumors. The company also develops a range of cytokine programs, including XTX202 (a modified IL-2), XTX301 (an IL-12 product candidate), and XTX401 (an IL-15 product candidate). These cytokine therapies are ingeniously engineered with a protein domain that keeps them inactive until proteases specific to the tumor microenvironment (TME) cleave this mask, thereby initiating their therapeutic activity. Xilio Therapeutics, Inc. was founded in 2016 and is based in Waltham, ... Massachusetts.
2026-08-12 07:30:00
Received FDA clearance of IND application for XTX501, a potential best-in-class bispecific PD-1 / masked IL-2 Advancing IND-enabling studies for potential first-in-class multi-specific, masked T cell engager programs targeting CLDN18.2 and PSMA+STEAP1; IND applications anticipated in the second half of 2027 Cash runway into the first quarter of 2028 expected to support key milestones across pipeline of next generation multi-specific I-O therapies WALTHAM, Mass., Aug. 12, 2026 (GLOBE NEWSWIRE) -- Xilio Therapeutics, Inc. (Nasdaq: XLO), a clinical-stage biotechnology company discovering and developing masked immuno-oncology therapies for people living with cancer, today announced pipeline progress and business updates and reported financial results for the second quarter ended June 30, 2026.
Xilio Therapeutics Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
2026-07-06 16:30:00
WALTHAM, Mass., July 06, 2026 (GLOBE NEWSWIRE) -- Xilio Therapeutics, Inc. (Nasdaq: XLO), a clinical-stage biotechnology company discovering and developing masked immuno-oncology therapies for people living with cancer, today announced that, effective July 1, 2026, the company granted non-qualified stock options to purchase 107,060 shares of its common stock to three new employees under Xilio Therapeutics' 2022 Inducement Stock Incentive Plan.
Xilio Therapeutics Appoints Ben Harshbarger as Chief Legal Officer
2026-06-29 07:30:00
WALTHAM, Mass., June 29, 2026 (GLOBE NEWSWIRE) -- Xilio Therapeutics, Inc. (Nasdaq: XLO), a clinical-stage biotechnology company discovering and developing masked immuno-oncology therapies for people living with cancer, today announced the appointment of Ben Harshbarger as chief legal officer.
Cancer Stocks That Are Advancing the Future of Oncology Care
2026-05-18 13:01:22
Oncology innovation is accelerating as AI, immunotherapy and targeted drugs drive growth for cancer-focused biotech and pharma stocks.
Xilio Therapeutics, Inc. (XLO) Reports Q1 Loss, Beats Revenue Estimates
2026-05-12 09:41:07
Xilio Therapeutics, Inc. (XLO) came out with a quarterly loss of $0.58 per share versus the Zacks Consensus Estimate of a loss of $0.66. This compares to a loss of $2.52 per share a year ago.
2026-05-12 07:30:00
On track for planned IND submission in mid-2026 and Phase 1 initiation in the second half of 2026 for XTX501, a potential best-in-class bispecific PD-1 / masked IL-2
Frequently Asked Questions
-
What is the current Xilio Therapeutics, Inc. (XLO) stock price?
-
Xilio Therapeutics, Inc.(NASDAQ:XLO) stock price is $8.87 in the last trading session. During the trading session, XLO stock reached the peak price of $12.74 while $6.468 was the lowest point it dropped to. The percentage change in XLO stock occurred in the recent session was --3.38% while the dollar amount for the price change in XLO stock was -$0.31.
-
XLO's industry and sector of operation?
-
The NASDAQ listed XLO is part of Biotechnology industry that operates in the broader Healthcare sector.
-
Who are the executives of XLO?
-
Uli Bialucha | Chief Scientific Officer
Ruth du Moulin | Senior Vice President of Medical Affairs
Katarina Luptakova | Chief Medical Officer
Christopher Frankenfield | Chief Financial Officer & Chief Operating Officer
Benjamin S. Harshbarger | Chief Legal Officer -
How many employees does XLO have?
-
Number of XLO employees currently stands at 76. XLO operates from 828 Winter Street, Waltham, MA 02451, US.
-
Link for XLO official website?
-
Official Website of XLO is: https://www.xiliotx.com
-
How do I contact XLO?
-
XLO could be contacted at phone #617 430 4680 and can also be accessed through its website. XLO operates from 828 Winter Street, Waltham, MA 02451, US.
-
How many shares of XLO are traded daily?
-
The average number of XLO shares traded daily for last 3 months was 43.68K.
-
What is the market cap of XLO currently?
-
The market value of XLO currently stands at $58.32M with its latest stock price at $8.87